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Objectives The aim of this study was to assess the prevalence of right-to-left (R to L) shunt in pa-
tients with visual aura and evaluate the effect of shunt closure on resolution of aura.
Background Right-to-left shunting is associated with migraine headache (MH) with aura. Some pa-
tients present with visual aura without headaches. It is unclear whether visual aura without head-
ache is a form of migraine or a transient neurologic dysfunction.
Methods Of patients referred to the University of California, Los Angeles for suspected patent fora-
men ovale (PFO), 225 had visual aura with or without MH. Patients were assessed for a shunt and
evaluated for MH and/or visual aura. They were divided into 3 groups: 1) visual aura associated with
MH; 2) visual aura unrelated in time to MH; and 3) visual aura without MH. The frequency of R to L
shunt was compared with a control group of 200 patients. Eighty patients underwent PFO closure.
Residual shunts, MH, and visual aura were reassessed after 3 and 12 months.
Results The prevalence of R to L shunt in Groups A, B, and C was 96%, 72%, and 67%, respectively,
versus 18% in the control group (p  0.0001). The frequency of shunting was similar in Group B
versus Group C, but much higher in all 3 groups compared with control subjects. Twelve months
after PFO closure, symptoms of aura were resolved in 52%, 75%, and 80% of patients in Groups A,
B, and C, respectively (p  NS).
Conclusions The similar distribution of R to L shunting in all 3 patient groups and the correlation
between PFO closure and improvement of aura suggests a similar pathophysiology between the
presence of PFO and the visual aura phenomenon, whether or not headache is present in the symp-
tom complex. (J Am Coll Cardiol Intv 2012;5:682–7) © 2012 by the American College of Cardiology
Foundation
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683Transient visual disturbances are associated with migraine
headache (MH) in 20% of people with migraine (1,2).
When these visual symptoms precede or occur during a
headache, they are recognized as visual aura associated with
migraine. However, there are some patients who develop
visual aura that is not associated with a headache. In these
cases, the patient or the physician might be concerned that
there is a primary ocular problem, such as a retinal tear,
transient ischemic event, or a cortical stroke.
There is an association of migraine with aura and
intracardiac or pulmonary shunting of blood from the
venous to systemic arterial circulation. Right-to-left (R to
L) shunting of blood, commonly through a patent fora-
men ovale (PFO), is present in 20% of the general
population (3–5). This proportion increases to 50% to
60% in people who have migraine associated with visual
aura (6 –9).
The purpose of this study was: 1) to determine the
frequency of R to L shunting in people who have visual
aura, either with or without migraine headaches; and 2) to
assess whether visual aura resolves after closure of R to L
shunt in patients who have these visual symptoms with or
without headache.
Methods
This study was approved by the Institutional Review Board.
The study population consisted of 590 patients referred to
the Interventional Cardiology program at UCLA between
2001 and 2011 for the assessment of conditions associated
with PFO, including cryptogenic stroke, migraines, decom-
pression illness, and orthodeoxia. Patients were assessed for
the presence of migraine headaches and visual aura and
specifically whether the transient visual symptoms occurred
with or without headaches. Patients were screened for the
presence of an R to L shunt by performing a transcranial
Doppler (TCD) study with a power M-mode Terumo 150
PMD machine (Spencer Technologies, Seattle, Washing-
ton). A mixture of 8 ml normal saline combined with 0.5 ml
of air and 1 ml of blood was agitated between 2 syringes
connected by a 3-way stopcock and injected into the
brachial vein; embolic tracks were then counted over the
middle cerebral arteries. The degree of R to L shunt was
evaluated by TCD at rest and with the Valsalva maneuver at 40
mm Hg, aided by visual feedback with a manometer device
(10). The Spencer logarithmic scale was used to grade the
results, where Grade 3 and higher (31 embolic tracks/60 s)
was considered positive for a significant shunt (11).
For the purpose of this study, visual aura was defined as
transient visual disturbance consisting of symptoms, includ-
ing positive features (e.g., flickering lights, spots, or lines)
and/or negative features (i.e., loss of vision). These symp-
toms were usually characterized by gradual development,
duration of no longer than 1 h, a mix of positive and enegative features, and complete reversibility (1). The re-
sponses of the patients were used to classify patients into 3
groups (Table 1):
Group A) Visual aura associated with migraine head-
ache: in this group of patients, the visual aura fulfilled
the diagnostic criteria of the International Classifica-
tion of Headache Disorders-2 (ICHD-2) for “typical
aura with migraine headaches.”
Group B) Visual aura not associated in time with
migraine headache: in this group, patients had both
visual aura and migraine headaches but without a
temporal association between them. Migraine head-
aches are present but are consistent with the ICHD-2
definition of: “Headache does not occur during aura
nor follow aura within 60 minutes.”
Group C) Visual aura without a history of migraine:
in this group, patients were characterized by the
presence of typical visual aura that is commonly
observed with migraine, but these patients were dis-
tinguished by having no history of headaches (1).
There were 80 patients with a
history of stroke or severe debil-
itating migraines who had their
PFO closed percutaneously.
Post-closure assessment con-
sisted of clinical evaluation and a
transesophageal echocardiogram
and TCD at 3 months. If there
was a residual shunt by TCD
Grade 3, then the TCD was
repeated at 3-month intervals up
to 1 year or until complete resolution of the shunt, as
evidenced by a negative TCD (Grade 0 to 2). After PFO
closure, the visual symptoms and migraines of the patients
were categorized under 4 subgroups: 1) “Resolved”: com-
plete resolution of visual aura (and headache where
applicable); 2) “Improved”: 50% reduction in the number
of aura events (and headache days/month where applicable); 3)
“Worse”: 50% increase in the number of aura (and
headache days/month where applicable); and 4) “No
Change”: symptoms remained the same (50% change)
after PFO closure.
Control population. The control population consisted of
00 patients (49% men) who were referred to the cardiac
atheterization laboratory for diagnostic catheterization that
as unrelated to the presence of a PFO. Patients who had
ardiac transplants were excluded from the control group,
ecause they might have had their PFO closed at the time
f surgery. Adults with a congenital heart disease known to
e associated with a shunt were also excluded from the
ontrol group. The patients were asked to undergo a TCD
Abbreviations
and Acronyms
ICHD  International
Classification of Headache
Disorders
MH  migraine headache
PFO  patent foramen ovale
R to L  right-to-left
TCD  transcranial Dopplerither before or after their catheterization procedure while
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684they were waiting in the recovery area. They signed the
Institutional Review Board-approved informed consent.
The prevalence of R to L shunt in the control group was
18%. The demographic data of the control group are shown
in Table 2. A history of migraine headaches was present in
11% of the control group, which is the expected prevalence
in a population of mixed sex (in large population studies,
18% of women and 6% of men have migraine). There was
only 1 patient in the control group who had a history of
visual aura without migraines.
Statistical analysis. Continuous variables were expressed as
ean  SD. Nominal and dichotomous variables were
xpressed as frequency percentage. The SPSS statistical
oftware (version 17.0, SPSS, Chicago, Illinois) was used for
-tailed Student t test comparison between the groups and
ontrol population; p value 0.05 was considered statisti-
ally significant. Odds ratio with 95% confidence interval
CI) was used to compare the probability of having R to L
hunt between the 3 study groups.
Table 1. Definitions of Relationship Between Migraine and Visual Aura
Group A
MH  aura
MH after visual aura or within 60 min
Group B
MH  aura (unrelated)
Migraine and visual aura but temporally unrelated
(i.e., not occurring within 60 min of each other)
Group C
Aura only
No history of migraine headache; only visual aura
MHmigraine headache.
Table 2. Clinical Descriptors of 3 Groups of Patients With Visual Aura
Group A
MH  Aura
Group B
MH  Aura
(Unrelated in Time)
n 175 29
Age, yrs 48 13 49 15
Male 56 (32%) 10 (35%)
Reason for referral
Stroke 121 (69.1%) 9 (31.0%)
Migraine 15 (8.6%) 1 (3.4%)
Transient neurologic 6 (3.5%) 3 (10.3%)
symptoms
Decompression 3 (1.7%) 1 (3.4%)
Orthodeoxia 2 (1.1%) 0 (0%)
Embolic event other than stroke 9 (5.2%) 2 (6.9%)
More than one reason 16 (9.1%) 6 (20.7%)
Other 3 (1.7%) 7 (2.4%)
Hypertension 27 (15%) 8 (28%)
Hyperlipidemia 27 (15%) 7 (24%)
Diabetes mellitus 7 (4%) 0 (0%)
Hypercoagulability† 36 (21%) 7 (24%)
Values are n, mean  SD, or n (%). *p value comparing combined study groups versus control su
pregnancy, factor V Leiden, prothrombin G20210A mutation, antiphospholipid antibodies, homoc
anticardiolipin AB, factor VIII activity, B2-glycoprotein-1 AB, and thrombocytosis.MHmigraine headache.esults
Of the 590 patients screened, there were 225 patients (38%)
who had visual aura with or without migraine; 91 (15%)
patients had migraine headache without aura. Table 2
provides the clinical descriptors of the 3 patient populations
and the control group. Table 3 further demonstrates the
number of patients with visual aura who tested positive for
an R to L shunt, the number of these patients who
underwent PFO closure, as well as the device used.
Although the prevalence of R to L shunting was similar
in Groups B versus C (p  0.66), Group A patients had a
significantly higher frequency of R to L shunting when
compared with the other 2 groups. The prevalence of R to
L shunt in Groups A, B, and C was significantly higher
than the prevalence of R to L shunt in the control group (36
of 200 [18%]) (p  0.0001). Compared with the control
ubjects, the odds ratio of having a PFO was 11.9 in Group
(95% CI: 4.9 to 29.1) and 9.1 in Group C (95% CI: 3.4
o 24.2). All 3 groups were highly selected, since most of
hese patients were referred to the interventional cardiology
epartment because of a pre-existing suspicion of a PFO,
hether due to an initial presentation with cryptogenic
troke or to a previously positive agitated saline bubble study
n transthoracic echocardiogram.
Among the 225 patients with visual aura, PFO closure
as performed in 80 patients (36%). This includes 67 of 168
40%) patients in Group A, 8 of 21 (38%) patients in Group B,
Group C
ura Only
Combined Study Groups
(Group ABC) Control Subjects p Value*
21 225 200
44 14 48 13 54 17 0.0001
2 (57%) 78 (35%) 98 (49%) 0.003
6 (28.6%) 136 (60.4%) — —
0 (0%) 16 (7.1%) — —
2 (9.5%) 11 (4.9%) — —
0 (0%) 4 (1.8%) — —
0 (0%) 2 (0.9%) — —
0 (0%) 11 (4.9%) — —
0 (0%) 22 (9.8%) — —
3 (50%) 23 (10.2%) — —
5 (24%) 40 (18%) 72 (36%) 0.0001
3 (14%) 37 (17%) 90 (40%) 0.0001
0 (0%) 7 (3%) 28 (14%) 0.0001
5 (24%) 48 (21%) 10 (5%) 0.0001
†Hypercoagulability states include use of oral contraceptive pill/hormone replacement therapy,
mia, protein S deficiency, protein C deficiency, elevated lipoprotein A, antithrombin III deficiency,A
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685and 5 of 14 (36%) patients in Group C. Table 4 demon-
trates the distribution of PFO closure and the outcomes of
his procedure in these patients, both at the 3- and 12-
onth follow-up, respectively.
3-month follow-up (post-PFO closure). At 3 months after
PFO closure, 60%, 25%, and 40% of patients in Groups A,
B, and C, respectively, experienced an improvement of
symptoms of migraine and visual aura (Fig. 1). Furthermore,
25%, 50%, and 40% of patients in Groups A, B, and C,
respectively, experienced complete resolution of symptoms by 3
months. Combining these values, the fraction of patients who
experienced either complete or partial (50%) resolution of
isual aura in Groups A, B, and C were 85%, 75%, and 80%,
espectively, at 3-month follow-up (p  ns, comparing the 3
roups). The observed improvement or resolution of symptoms
oincided with the disappearance of the R to L shunt.
12-month follow-up (post-PFO closure). Symptoms of mi-
raine aura and headache continued to improve over time after
losure of the PFO (Fig. 2). The observed resolution or improve-
ent of symptoms coincided with resolution of the R to L shunt.
In Groups A, B, and C, 75%, 100%, and 100% of patients,
espectively, who experienced an improvement in symptoms by
months were completely free from visual aura at the 12-
onth follow-up. This was true if the visual aura was either
ssociated with migraine or was independent of the presence of
eadache. The improvement/resolution of visual aura coin-
ided with improvement/resolution of migraine headache in
very patient except in 2 cases.
Table 3. Frequency of R to L Shunt in 3 Groups of Patients With Visual Au
Group A MH  Aura Group B
n 175
Positive for R to L shunt 168 (96%)
(p 0.0001)*
R to L shunts that were closed 67 (40%)
PFO closure device used
CardioSEAL/Amplatzer/Helex
9/34/24
Values are n or n(%). *p value comparing each group versus control subjects.
MHmigraine headache; PFO patent foramen ovale; R to L right-to-left.
Table 4. Effect of PFO Closure on Patients With Visual Aura
Group A
(MH  Aura)
3-Month 12-Month
PFO closed, n 67
Resolved 17 (25%) 35 (52%)
Improved 40 (60%) 16 (24%)
No change 3 (4.5%) 1 (1.5%)
Worse 4 (6.0%) 3 (4.5%)
Data unavailable 3 (4.5%) 12 (18%)
Values are n or n (%).Abbreviations as in Table 3.By the 12-month follow-up, 52%, 75%, and 80% of
atients in Groups A, B, and C, respectively, had complete
esolution of symptoms.
The proportion of patients who experienced either com-
lete or partial resolution of their symptoms by the 12-
onth mark was 76% in Group A, 75% in Group B, and
0% in Group C (p  NS, comparing all 3 groups).
iscussion
Migraine headache, present in approximately 12% of the
general population, is one of the most frequent causes of
disability in the United States (4). Among people with
migraine, 20% describe transient visual deficits or aura that
usually precede the headache but can occur simultaneously
with the head pain (1,2). Our patient population had a higher
proportion of migraine with aura (38%) as opposed to migraine
without aura (15%). This might be due to selection bias of our
patient population toward PFO-positive patients, which is
consistent with prior observations that PFO is associated with
typical migraine with aura (6–9).
Some migraineurs describe visual aura as a phenomenon
that occurs independently in time from their headache. Ac-
cording to the ICHD, the headache and the aura must be
separated at least by 1 h to fit this category. It is much less
common to encounter people who deny ever having a headache
but describe the same visual disturbances as reported in the
migraineurs with aura. Because it is difficult to measure a
Number of PFOs Closed Versus Control Subjects
 Aura (Unrelated) Group C Aura Only Control Subjects
29 21 200
1 (72%)
0.0001)*
14 (67%)
(p 0.0001)*
36 (18%)
8 (38%) 5 (36%) 0 (0%)
0/3/5 1/0/4 —
Group B
(MH Unrelated to Aura)
Group C
(Aura Only)
nth 12-Month 3-Month 12-Month
8 5
%) 6 (75%) 2 (40%) 4 (80%)
%) 0 (0%) 2 (40%) 0 (0%)
.5%) 1 (12.5%) 0 (0%) 0 (0%)
.5%) 0 (0.0%) 0 (0%) 0 (0%)
) 1 (12.5%) 1 (20%) 1 (20%)ra and
MH
2
(p3-Mo
4 (50
2 (25
1 (12
1 (12
0 (0%
s
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686headache, it is unknown whether these 3 types of visual aura
are due to the same mechanism of cortical spreading depres-
sion. Many headache specialists assume that they are similar
and call the isolated visual auras “visual migraines.” Migraine
visual aura without headache is present in 3.2% of the general
population (2). This is similar to the frequency of people in our
tudy population who presented with symptoms of visual
igraines without headaches, 3.6% (21 of 590).
In this study, we observed:
1. Right-to-left shunting is present in approximately
18% of a control population as represented by adults
without congenital heart disease who are referred for
cardiac catheterization.
2. Right-to-left shunting occurs at a higher frequency
than in control subjects (p  0.0001) in patients with
visual aura referred for evaluation of PFO. The frequency
of R to L shunting is similar among the 3 categories of
patients who present with visual aura (p  ns).
3. Patent foramen ovale closure results in a similar degree of
improvement of visual aura among patients presenting
with visual aura associated with migraine headache,
visual aura unrelated in time to headache, and migraine
visual aura without headache. The resolution of symp-
toms of aura coincided with the absence of a residual
shunt on TCD. Although the magnitude of improve-
ment could be due to a placebo effect, the outcome of
PFO closure was similar in all 3 groups. Only a random-
ized double-blind trial would be able to distinguish the
true effect of PFO closure in these patients.
The purpose of this study was to determine the prevalence of
R to L shunt in patients with visual aura with and without
migraine headaches and to assess whether the aura resolves
after transcutaneous PFO closure. Because a link between
PFO and acephalgic migraines has never been documented in
Figure 1. Effect of PFO Closure at 3-Month Follow-Up
Signiﬁcant improvement (Group A) and resolution (Group B and Group C)
of visual aura symptoms observed 3 months after patent foramen ovale
(PFO) closure.prior studies, a link between the 2 conditions would be a novelobservation. The common descriptor of R to L shunting
indicates a similar pathophysiology for the 3 groups of people
who have visual aura with or without headache.
Prior studies document an association between PFO and
migraine headache with aura (6–9). This study extends this
observation to include all visual auras, regardless of the
presence of headache. We suspect that many transient
neurologic deficits— with or without headache— in pa-
tients who have a PFO, may be manifesting a similar
phenomenon as these patients with visual aura. We hypoth-
esize that there is a spectrum of migraine cortical spreading
depression that induces transient neurologic deficits, which
may have visual, sensory, or motor components. These auras
are due to chemical stimulants that pass through a PFO and
bypass metabolism in the lung vasculature. These episodes
may be difficult to distinguish clinically from transient
ischemic attacks (which presumably are due to emboli) since
both conditions are transient and leave no trace on magnetic
resonance imaging.
The agreement on association between R to L shunt and
migraine headache with aura is not unanimous (12–14). Garg
et al. (12) determined the presence of PFO in patients with a
well-defined history of migraine headaches. According to their
results, not only was there no association between migraines
and PFO but also no association between migraines and either
the severity of shunting or presence of aura.
The MIST (Migraine Intervention with STARFlex
Technology) trial was a randomized, double-blinded, sham-
controlled trial that was undertaken to determine the benefit
of PFO device closure compared with a sham procedure (15).
In this controversial study, no significant difference was noted
in the primary outcome of headache cessation between the 2
groups. Some investigators do not consider the MIST results
to be conclusive, due to possible incomplete closure of the
interatrial shunt in up to 35% of these patients (16). Separate
reports demonstrate a residual shunt in over 28% of patients
after PFO closure when devices similar to STARFlex (such as
Figure 2. Effect of PFO Closure at 12-Month Follow-Up
Observed resolution of the visual aura symptoms at 12-month follow-up.
PFO  patent foramen ovale.
11
1
1
1
1
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 6 , 2 0 1 2 Khessali et al.
J U N E 2 0 1 2 : 6 8 2 – 7 Effect of PFO Closure on Aura
687CardioSEAL and BioStar [Nitinol Medical Technologies,
Boston, Massachusetts]) are used (17). Furthermore, the
MIST trial included patients with severe refractory migraine
with no other indication for PFO closure; this population was
different from our observational study.
Study limitations. The prevalence of R to L shunt was
higher than expected, due to the study population being
selected for PFO-related conditions—be it due to crypto-
genic stroke, decompression illness, or debilitating mi-
graines. Furthermore, significant loss of data occurred,
especially at the 12-month follow-up. Of 80 patients who
had their PFO closed, 14 (17.5%) were lost to follow-up at
the 12-month interval. There might have been more pa-
tients whose visual aura resolved after PFO closure. Thus,
the number of patients who benefited from PFO closure
might have been underestimated.
Conclusions
These observations support the hypothesis that the phenom-
enon of migraine aura without headache might be causally
linked to R to L shunting in most cases. However, R to L
shunting of blood is not the only mechanism that produces
visual aura, because we observed 7 of 21 (33%) people who had
visual aura without headache but no evidence for R to L
shunting. But the high prevalence of R to L shunting in this
population, 3 the observed frequency in the control group, is
consistent with the hypothesis that intermittent R to L
shunting through a PFO permits chemical substances that are
usually cleared by the lungs, to bypass the metabolism in the
lungs and reach the brain at a higher concentration via direct
entry into the arterial circulation (12). The mechanism is
consistent with the high correlation between PFO and mi-
graine with aura and might explain why visual aura symptoms
are frequently alleviated after PFO closure.
Reprint requests and correspondence: Dr. Jonathan Tobis, Depart-
ment of Medicine, UCLA Medical Center, B976 Factor Building
CHS, 10833 Le Conte Avenue, Los Angeles, California 90095.
E-mail: jtobis@mednet.ucla.edu.
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